EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Coccidioidal Peritonitis: Clinical Characteristics, Treatment and Outcomes

Jamilah L Shubeilat iD, Sandhya R Nagarakanti iD, Abeer Almajali, Jaxon K Quillen iD, Matthew R Buras iD, Lisa Speiser, Janis Blair iD

Journal of Fungi · 03.07.2026 · 12 (7) · 489

DOI: 10.3390/jof12070489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 03.07.2026. Verfasst von Jamilah L Shubeilat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ 85045, USA. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peritoneal coccidioidomycosis is a rare, disseminated manifestation of Coccidioides infection with limited representation in the literature. We report 37 proven or probable cases from a single institution, including 12 patients (32%) with immunosuppression. Thirty-six patients received antifungal therapy, all of whom demonstrated clinical response. Among 11 (29.7%) patients who completed and stopped therapy after a median duration of 26 months, 2 (5%) experienced a relapse and were successfully retreated. Nine patients (24%) had no known relapse. Thirteen patients (35%) required modification of antifungal regimens, primarily due to azole adverse effects. Treatment approaches and median duration of therapy (57 months) were similar between immunosuppressed and non-immunosuppressed groups. No deaths were attributable to infection. Overall, outcomes were favorable, with strong clinical responses to azole therapy. Patients without identifiable immunologic deficits or additional sites of dissemination, when managed with antifungal therapy and close clinical, radiologic, and serologic monitoring, may achieve good prognosis, particularly when indefinite azole therapy is not feasible.

Schlagwörter

Stichwörter der Autor:innen

Coccidioidesantifungal treatmentcoccidioidomycosisdisseminated infectionperitonealperitonitis

Autor:innen und Institutionen

  • Division of Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ 85045, USA.
  • Department of Quantitative Health Services, Division of Clinical Trials and Biostatistics, Mayo Clinic-Samuel C. Johnson Research Center, Scottsdale, AZ 85059, USA.

ORCID-Profile: Jamilah L Shubeilat, Sandhya R Nagarakanti, Jaxon K Quillen, Matthew R Buras, Janis Blair

Zitieren

APA

Shubeilat, J. L., Nagarakanti, S. R., Almajali, A., Quillen, J. K., Buras, M. R., Speiser, L., & Blair, J. (2026). Coccidioidal Peritonitis: Clinical Characteristics, Treatment and Outcomes. Journal of Fungi, 12(7), 489. https://doi.org/10.3390/jof12070489

Vancouver

Shubeilat JL, Nagarakanti SR, Almajali A, Quillen JK, Buras MR, Speiser L, et al. Coccidioidal Peritonitis: Clinical Characteristics, Treatment and Outcomes. Journal of Fungi. 2026;12(7):489. doi:10.3390/jof12070489

BibTeX
@article{Shubeilat2026,
  author = {Shubeilat, Jamilah L and Nagarakanti, Sandhya R and Almajali, Abeer and Quillen, Jaxon K and Buras, Matthew R and Speiser, Lisa and Blair, Janis},
  title = {Coccidioidal Peritonitis: Clinical Characteristics, Treatment and Outcomes},
  journal = {Journal of Fungi},
  year = {2026},
  volume = {12},
  number = {7},
  pages = {489},
  doi = {10.3390/jof12070489}
}
Kostenlos starten →